The etiology of uHCC is multi-factorial and encompasses both viral and non-viral causes. Common to both is liver damage with the development of cirrhosis. Viral causes include hepatitis B (HBV) and hepatitis C (HCV), while non-viral causes include nonalcoholic steatohepatitis (NASH), alcohol-induced cirrhosis, tobacco use, diabetes, and obesity. The most common of these in the US are HCV, alcohol, and NASH. More effective uHCC treatment options that address viral and non-viral etiology are needed.1,2
Could a next-generation treatment help maximize OS?
Incidence of liver cancer is projected to increase
137%
over the next decade3
Despite emerging therapies, an urgent need remains for more targeted therapy options that are highly selective and can be used in combination therapy, including immunotherapy.4,5
Future Treatment Options
By 2029, regimens that combine an immune checkpoint inhibitor with an angiogenesis inhibitor will carry a large share of overall prescriptions.6
Checkpoint inhibitor and TKI combinations offer promise because toxicity profiles do not overlap.7
What will the future of uHCC treatment hold for families like Greg and Sarah?
In this inspiring, short video, Sarah shares her family’s uHCC journey and the importance of cherishing each moment.
Stay Connected
Sign up to receive information, company news and updates, or to connect with a member of our team.
REFERENCES: 1. Massarweh NN, El-Serag HB. Cancer Control. 2017;24(3):1073274817729245. 2. Cheng AL, Qin S, Ikeda M, et al. J Hepatol. 2022;76(4):862-873. 3. Weinfurtner K, Dodge JL, Yao FYK, Mehta N. Transplant Direct. 2020;6(10):e605. 4. Zhou Z, Li M. BMC Med. 2022;20(1):90. 5. Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Signal Transduct Target Ther. 2020;5(1):146. 6. Sadhu A, Blandy O. Decisions Resources Group. Published November 20, 2020. 7. Zhu XD, Tang ZY, Sun HC. Genes Dis. 2020;7(3):328-335.
